Citations 1
Long-term follow-up of a phase I/II trial of radioimmunotherapy (RIT) with yttrium 90 ( 90 Y) ibritumomab tiuxetan for CD20+ B-cell non-Hodgkin's lymphoma (NHL)
Emmanouilides, Christos, Raubitschek, Andrew, Darif, Mohamed, Schilder, Russell J., Wiseman, Gregory A., Gordon, Leo I. , Molina, Aurelia Alañón , White, C. A., Witzig, Thomas E.
Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 6574-6574
